Premium
Clobetasol Propionate Versus Fluocinonide Creams in Psoriasis and Eczema
Author(s) -
Jegasothy Brian,
Jacobson Coleman,
Levine Norman,
Millikan Larry,
Olsen Elise,
Pinnell Sheldon,
Cole Gary,
Weinstein Gerald,
Porter Marvin
Publication year - 1985
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1985.tb05821.x
Subject(s) - clobetasol propionate , medicine , psoriasis , dermatology , morning , corticosteroid , surgery
A double‐blind, parallel comparison was made of the short‐term efficacy and safety of three times daily regimens of 0.05% clobetasol propionate cream and 0.05% fluocinonide cream in 114 adolescent and adult patients with psoriasis and 113 with eczema. After 2 weeks of topical applications, patients were assessed according to (1) investigators' overall judgment of clinical response, (2) degree of severity of specific signs and symptoms, and (3) patients' evaluation of improvement. In all three response categories in psoriasis, and in two of three in eczema, clobetasol was statistically significantly superior to fluocinonide (p < 0.05‐p < 0.001). Healing commenced more rapidly with clobetasol and there was no indication of tachyphylaxis. In contrast, the healing rate with fluocinonide slowed noticeably after the first week, and there was a greater tendency to relapse following fluocinonide treatment. Both regimens were safe: drug‐related side effects were generally mild and occurred most commonly with fluocinonide therapy in eczema patients. Overall, drug‐related effects occurred in 4% of patients receiving clobetasol and 12% receiving fluocinonide (p < 0.05). Transient morning plasma cortisol reductions below 5 μg/dl occurred in 6% of clobetasol‐treated patients, reverting to normal within 1 week of the end of treatment.